Quantitative MRI for Myelofibrosis
Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment
University of Michigan Rogel Cancer Center
192 participants
Dec 22, 2014
OBSERVATIONAL
Conditions
Summary
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Eligibility
Inclusion Criteria5
- Male /female subjects over the age of 18
- Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
- No contraindications to MRI
- Able to undergo MRI without anesthesia
- \-
Exclusion Criteria3
- Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
- Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months. Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01973881